Neoadjuvant breast cancer treatment response; tumor size evaluation through different conventional imaging modalities in the NeoDense study
(2020) In Acta Oncologica 59(12). p.1528-1537- Abstract
- Neoadjuvant chemotherapy (NACT) is offered to an increasing number of breast cancer (BC) patients, and comprehensive monitoring of treatment response is of utmost importance. Several imaging modalities are available to follow tumor response, although likely to provide different clinical information. We aimed to examine the association between early radiological response by three conventional imaging modalities and pathological complete response (pCR). Further, we investigated the agreement between these modalities pre-, during, and post-NACT, and the accuracy of predicting pathological residual tumor burden by these imaging modalities post-NACT.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7d0f246f-5102-46d6-91f9-2f887a2088e1
- author
- Dalene Skarping, Ida LU ; Förnvik, Daniel LU ; Heide-Jørgensen, Uffe ; Ryden, Lisa LU ; Zackrisson, Sophia LU and Borgquist, Signe LU
- organization
-
- Breastcancer
- LUCC: Lund University Cancer Centre
- Breast cancer prevention & intervention (research group)
- Medical Radiation Physics, Malmö (research group)
- Breast cancer treatment
- The Liquid Biopsy and Tumor Progression in Breast Cancer (research group)
- Breast Cancer Surgery (research group)
- Surgery (Lund)
- EpiHealth: Epidemiology for Health
- Radiology Diagnostics, Malmö (research group)
- publishing date
- 2020-10-16
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Acta Oncologica
- volume
- 59
- issue
- 12
- pages
- 10 pages
- publisher
- Taylor & Francis
- external identifiers
-
- scopus:85092762533
- pmid:33063567
- ISSN
- 1651-226X
- DOI
- 10.1080/0284186X.2020.1830167
- language
- English
- LU publication?
- yes
- additional info
- © 2020 The Author(s).
- id
- 7d0f246f-5102-46d6-91f9-2f887a2088e1
- date added to LUP
- 2020-10-21 08:06:26
- date last changed
- 2022-05-12 07:09:21
@article{7d0f246f-5102-46d6-91f9-2f887a2088e1, abstract = {{Neoadjuvant chemotherapy (NACT) is offered to an increasing number of breast cancer (BC) patients, and comprehensive monitoring of treatment response is of utmost importance. Several imaging modalities are available to follow tumor response, although likely to provide different clinical information. We aimed to examine the association between early radiological response by three conventional imaging modalities and pathological complete response (pCR). Further, we investigated the agreement between these modalities pre-, during, and post-NACT, and the accuracy of predicting pathological residual tumor burden by these imaging modalities post-NACT.}}, author = {{Dalene Skarping, Ida and Förnvik, Daniel and Heide-Jørgensen, Uffe and Ryden, Lisa and Zackrisson, Sophia and Borgquist, Signe}}, issn = {{1651-226X}}, language = {{eng}}, month = {{10}}, number = {{12}}, pages = {{1528--1537}}, publisher = {{Taylor & Francis}}, series = {{Acta Oncologica}}, title = {{Neoadjuvant breast cancer treatment response; tumor size evaluation through different conventional imaging modalities in the NeoDense study}}, url = {{http://dx.doi.org/10.1080/0284186X.2020.1830167}}, doi = {{10.1080/0284186X.2020.1830167}}, volume = {{59}}, year = {{2020}}, }